ECCO'25 Abstracts

ECCO'25 Abstracts on the JCC Website

ECCO'25 Abstract Book PDF Version

ECCO'25 Abstracts COI Disclosure

ECCO'24 Abstracts

ECCO'24 Abstracts on the JCC Website

ECCO'24 Abstract Book PDF Version

ECCO'24 Abstracts COI Disclosure

Poster Presentations: Basic Science 2023

P001 Obefazimod upregulates miR-124 and downregulates the expression of some cytokines in blood and rectal biopsies of patients with moderate-to-severe ulcerative colitis.

P002 Exclusive Enteral Nutrition, the gut microbiome and corticosteroid response in patients with acute severe colitis

P003 MicroRNAs as biomarkers in Inflammatory Bowel Disease unclassified (IBDU) patient samples may predict the development from IBDU to Crohn’s Disease or Ulcerative Colitis

P004 Untargeted serum metabolome shows Crohn Disease (CD) associated signature, signals that correlate with disease activity and CRP, and signals that may precede disease flare

P005 Molecular-based classification of ulcerative colitis and its dynamic

P006 Engineered propionate-producing bacteria attenuates murine colitis by modulating the immune function of resident macrophages via histone deacetylase

P007 Paradoxical effects of high and low emulsifier diets on intestinal permeability in unstressed and stressed states in healthy human adults: a pilot randomised controlled feeding trial.

P008 Fibrostricturing Crohn’s disease is characterised by an imbalance in active eosinophils, Th1, Th2 and regulatory T cells

P009 IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells

P011 Patient-derived organoids as an epithelial model for preclinical IBD research and drug development.

P012 The administration of mm-miR-378a-3p exacerbates chronic inflammation and fibrosis in a murine intestinal model

P013 Role of IL-36RA mutations in Crohn’s disease

P014 Behaviour in mice with chronic DSS colitis mimics fatigue in IBD and is associated with neuroinflammation

P015 CITE-seq analysis revealed immune cell diversity in colonic mesenteric lymph nodes from IBD patients

P016 Dietary supplementation with Brazilian jaboticaba-sabará fruit (Myrciaria jaboticaba (Vell.) O. Berg) ameliorates colitis-driven colorectal cancer in mice

P017 Fecal wash host transcriptomics identifies inflammation throughout the colon and terminal ileum

P018 Expression of annexin A1 and NLRP3 inflamassome in Chron's disease

P019 Host-Enterobacteriaceae interactions and mitochondrial dysfunction in Crohn’s colitis

P020 Characterisation of mucus in patients with Crohn’s disease

P021 Microbial metabolite receptors as mediators of pathogenic processes in Inflammatory Bowel Disease.

P022 A correlation of serum Fibroblast Growth Factor 21 level with inflammatory markers and indicators of nutritional status in patients with Inflammatory Bowel Disease

P023 Immune-metabolic profiles of creeping fat in relation to degree of severity in Crohn's disease postsurgical recurrence.

P024 Effects of anti-TNF and anti-interleukins 12 and 23 drugs on circulating dendritic cells migratory capacity in inflammatory bowel disease

P025 Colonic rather than ileal expression of ITGA4/ITGB7 correlates with local intestinal inflammation in IBD

P026 Cost per Response/Remission analysis of biologic therapies availables in Argentina for the treatment of Bio-exposed patients with moderate-to-severe active Ulcerative Colitis

P027 Anorectal Motility Disorders in Inflammatory Bowel Disease patients

P028 Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease – what is the opportunity cost of improving access to health care?

P029 Histopathological characterization of a chronic DSS-induced mouse model of IBD with intestinal fibrosis

P030 Assessing dietetic interventions in inflammatory bowel disease patients

P031 CKD-506, a new histone deacetylase 6 inhibitor, suppresses immune cells and restores intestinal epithelial function

P032 Distinct immune cell trigger responses in Ulcerative Colitis – Results from an in vivo human intestinal injury model

P033 The assessment of serum cytokines at baseline could predict mucosal healing in patients with Crohn's disease treated with ustekinumab. A prospective study.

P034 A common IL2RA polymorphism alters natural killer cell immunophenotype and function in Crohn’s disease, with implications for IL-2 based therapy

P035 Anti-inflammatory Effect and Mechanism of Action of BMC333, a Rationally-Designed Live Bacterial Consortium Based on Microbiome Functional Genomic Analysis for Treating IBD

P036 Analysis of intestinal tissue from newly diagnosed patients with inflammatory bowel disease reveals distinct proteomic profiles

P037 Enhancing the efficacy of cannabidiol using protein nanoparticles to treat inflammatory bowel disease

P038 Notch pathway in fibrosis: a new anti-fibrotic therapy in Crohn's disease?

P039 The disappearance of cell death brakes in inflammatory bowel disease: a step towards molecular healing

P040 Caspase-8 blockade attenuates NSAID-induced colitis and cell death via NLRP3 inflammasome and NF-κB activation

P041 The upregulation of tissue factor in colonic mesenchymal cells in active ulcerative colitis is associated with severe and resistant to treatment disease, but tofacitinib has not effect on it

P042 Distinct gene expression profile associated to inflammation and neoplastic progression in longstanding ulcerative colitis

P043 ALI culture derived from human organoids recapitulates cell composition during intestinal crypt formation

P044 Ex vivo effects of infliximab on the long non-coding RNAs expression levels in Crohn´s disease

P045 Local administration of extracellular vesicles from adipose-derived stromal cells promote healing in a rat model of radiation colitis – a pilot study

P046 Crohn Disease (CD) untargeted fecal metabolome shows strong correlation with specific salivary associated microbial taxa, and with disease activity

P047 Osteopontin in colitis-associated carcinoma (CAC)

P048 Deep phenotyping of the peripheral immune cell compartment in Crohn‘s Disease

P049 Proteomic characterization of serum extracellular vesicles from newly diagnosed patients with inflammatory bowel disease

P050 Intraperitoneally injected 3-dimensional cultured tonsil-derived mesenchymal stem cells in murine colitis model form aggregates with mouse immune cells: A preliminary study

P051 Immune phenotypes in acute severe ulcerative colitis

P052 IL-12p70 as a potential driver of pathogenic IL-17+IFNγ+ mucosal memory TIGITneg T cells in a subgroup of severe CD patients

P053 Ustekinumab decreases circulating Th1, Th17, and MAIT cells in Crohn’s disease

P054 Secreted inflammatory protein profiles following treatment of ex-vivo human inflammatory bowel disease explants with licenced biologic therapies

P055 Exosomal miR-103a-3p from Crohn’s creeping fat-derived ASCs contributes to intestinal fibrosis by targeting TGFBR3 and activating fibroblasts

P056 Exposures linked with urban and rural living indicate that living in rural area but spending above 50% of daily-life in urban environment is linked with reduction in alpha-diversity, reduced rural index, and reduced microbial health index mirroring C

P057 Development and evaluation of the i-Tracker Certolizumab and i-Tracker Anti-Certolizumab kits: rapid and innovative tests intended for monitoring patients treated with Certolizumab.

P058 Immunological effects of hepatitis B virus vaccination in inflammatory bowel disease patients

P059 Klebicin as a novel therapy for Klebsiella infection management

P060 Restoration of occludin and claudin-1 expression in patients with Crohn’s disease receiving anti-TNF treatment.

P061 Response to anti-α4β7 therapy in Ulcerative colitis is associated with lymphoid aggregate attrition through impaired recruitment of naïve lymphocytes

P062 Antibody responses to SARS-CoV-2 vaccination outperform responses induced by natural infection in patients with IBD receiving immunosuppressive medications: a report from the ICARUS-IBD consortium.

P063 Host-mycobiome interactions during the resolution of inflammation in experimental colitis

P064 High intestinal Secretory Leukocyte Protease Inhibitor (SLPI) expression correlates with abundant neutrophilic inflammation and identifies Inflammatory Bowel Disease patients with a strong IL-17 response.

P065 Altered B cell expansion and maturation in Crohn’s disease

P066 ON104, a novel bioengineered antibody targeting oxidized Macrophage Migration Inhibitory Factor (oxMIF) shows efficacy in two distinct models of experimental colitis

P067 Fractal analysis of extracellular matrix as a new histological method for observer-independent quantification of intestinal fibrosis in Crohn’s Disease

P068 Polyunsaturated fatty acid excess fuels pro-inflammatory transcriptional networks in GPX4 deficient intestinal epithelial cells

P069 Elevated adaptive immune responses to multiple Lachnospiraceae bacterial flagellins in therapy-naïve pediatric CD patients are associated with distinct immune pathology.

P070 Global cytokine—cytokine interaction framework to uncover communication channels between elements of the immune system

P071 T-cell, B-cell and monocytic infiltrations of myenteric plexus in IBD

P072 : Circadian misalignment by simulated night shifts decreases colonoid barrier integrity in Ulcerative Colitis

P073 Let´s talk about sex: an unicentric cross-sectional study on sexual dysfunction, sexual satisfaction and body schema disorders in Inflammatory Bowel Disease

P074 Interferon-γ promotes antigen processing and presentation pathway in the intestinal epithelium of patients with Crohn’s disease

P075 Characterisation and structural analysis of a new murine model to study postoperative fibrotic recurrence in Crohn’s disease combining ileocecal resection with chronic colitis

P076 Abdominal pain severity for IBD in remission correlates with genetic clustering and enzymatic activity of faeces-derived Candida albicans strains

P077 Group 1 innate lymphoid cells in creeping fat of Crohn’s disease

P078 Physiological hypoxia improves growth and functional differentiation of human intestinal epithelial organoids.

P079 Attenuation of inflammation and histologic production-dependent improvement by engineered high acetate producing Saccharomyces boulardii in DSS-induced colitis

P080 Mucosal clock and inflammation regulatory genes are disrupted in treatment naïve pediatric patients with ulcerative colitis

P081 The application of multiomics to investigate the evolution of inflammatory bowel disease in pediatric and adult patients

P082 The CCR9/CCL25 axis is specific to the ileum and is correlated with stricturing disease

P083 JAK/STAT pathway and IL-6 activity in moderate to severe Ulcerative Colitis

P084 Response to appendectomy in refractory Ulcerative Colitis appears based on two distinct inflammatory phenotypes

P085 Gut microbiota profile changes in patients with Ulcerative Colitis

P086 Sirtuin 7 inhibitor attenuates colonic mucosal immune activation in mice–potential therapeutic target in Inflammatory Bowel Disease

P087 Calcitonin gene related peptide beta (CGRPβ): a new player in inflammatory bowel disease pathophysiology

P088 Restoration of gut microbiota and changes in inflammatory susceptibility by dextran sulfate sodium after antibiotic treatment in mice

P089 Colonic explant lactate concentration and inflammatory protein secretion in ulcerative colitis

P090 Low-density neutrophils are higher in individuals with active ulcerative colitis

P091 Gender focused investigation of sexual dysfunction, sexual satisfaction and body schema disorders in male and female patients with Inflammatory Bowel Disease

P092 Punica Granatum affects gut biofilm-forming bacteria and promotes intestinal mucosal healing regulating the crosstalk between epithelial cells and intestinal fibroblasts

P093 Creeping fat-derived long chain free fatty acids drive intestinal muscularis propria muscle cell proliferation via carnitine palmitoyltransferase 1 (CPT-1) – a relevant mechanism for stricturing Crohn’s disease

P094 Impacts of 5-aminosalicylic acid on the intestinal microbiota leading to the anti-inflammatory effect

P095 Newly discovered gut matrikines from Crohn’s disease intestinal tissue induce cell proliferation, activation and inflammatory response in intestinal myofibroblasts in vitro

P096 Characterization of suppressive immune cell subsets in mouse models of colitis-associated colorectal cancer

P097 Various regulatory single nucleotide polymorphisms regulate similar biological pathways in Crohn’s disease

P098 Novel drug candidate for the treatment of Inflammatory Bowel Disease with unique mechanisms of action

P099 IL-33 activates CD73-expressing cells promoting tumorigenesis during colitis-associated colorectal cancer

P100 Atypical Anti-Neutrophil Cytoplasmatic Antibodies Are Antibodies Against Neutrophil Extracellular Traps: A Novel Pathophysiological Mechanism In Ulcerative Colitis

P101 Circulating MicroRNA-16 in Inflammatory Bowel Disease Patients - Potential Biomarker to Assess Inflammation

P102 A small molecule selective integrin α4β7 inhibitor demonstrates efficacy in a chronic model of Inflammatory Bowel Disease

P103 Colitis-associated faecal miRNAs are mediators of host-microbiota interactions and key regulators of intestinal permeability and inflammation

P104 Exploring the transcriptomic miRNA signatures of Egyptian Inflammatory Bowel Disease patients

P105 Epithelial microRNA signatures as potential biomarkers in Crohn’s disease related to clinical and endoscopic activity

P106 Identification of urine and serum diagnostic biomarkers of inflammatory bowel disease using a proteomic approach

P107 Decreased epithelial keratinization contributes to defective wound healing in Crohn's disease fistula

P108 Development and evaluation of the i-Tracker Risankizumab and i-Tracker Anti-Risankizumab kits: rapid and innovative tests intended for monitoring patients treated with Risankizumab.

P109 Using baseline Peripheral blood mononuclear cell (PBMC) transcriptomics of Crohn Disease patients receiving Ustekinumab treatment as a tool to assess potential response at 1 year

P110 Fibroblast activation protein is strongly expressed in intestinal fibrosis in inflammatory bowel disease patients

P111 Efficacy of a novel long-acting lipidated interleukin-22, alone and in combination with anti-TNF treatment, in a murine chronic DSS colitis model

P112 S1PR expression on circulating immune cells is not limited to lymphocytes in patients with inflammatory bowel disease

P113 Protein fingerprint biomarkers of collagen remodeling can evaluate fibrogenesis in an in vitro colonic scar-in-a-jar model

P114 Increased serum levels of the migraine biomarker calcitonin gene related peptide alpha in a newly diagnosed inflammatory bowel disease population: a new mediator for the gut-brain-axis

P115 Trehalose modulates Dextran Sulfate Sodium-induced colitis by regulating macrophage polarization

P116 RIPK3 - a new marker for assessment of ulcerative colitis severity

P117 Low-Intensity Pulsed Ultrasound as a new approach of gut disruptive liquid biopsy to boost the release of mucosal extracellular vesicles in Ulcerative Colitis

P118 Induction of ETS1 and senescence associated secretory phenotype in human intestinal fibroblasts

P119 Perianal Crohn’s disease and the development of colorectal and anal cancer: A systematic review and meta-analysis